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Background: The mechanism underlying the association of triacylglycerol storage and insulin resistance is unclear.
Results: Increasing phosphatidic acid (PA) in primary hepatocytes via de novo synthesis or action of phospholipase D or
diacylglycerol kinase- disrupts insulin signaling.
Conclusion: PA derived from different sources inhibits insulin signaling.
Significance: Increases in hepatocyte PA may mechanistically link lipid storage and insulin action.
Although an elevated triacylglycerol content in non-adipose
tissues is often associated with insulin resistance, the mechanis-
tic relationship remains unclear. The data support roles for
intermediates in the glycerol-3-phosphate pathway of triacyl-
glycerol synthesis: diacylglycerol (DAG), which may cause insu-
lin resistance in liver by activating PKC, and phosphatidic acid
(PA), which inhibits insulin action in hepatocytes by disrupting the
assembly of mTOR and rictor. To determine whether increases in
DAG and PA impair insulin signaling when produced by pathways
other than that of de novo synthesis, we examined primary mouse
hepatocytes after enzymatically manipulating the cellular content
of DAG or PA. Overexpressing phospholipase D1 or phospholipase
D2 inhibited insulin signaling and was accompanied by an elevated
cellular content of total PA, without a change in total DAG. Over-
expression of diacylglycerol kinase- inhibited insulin signaling
and was accompanied by an elevated cellular content of total PA
and a decreased cellular content of total DAG. Overexpressing
glycerol-3-phosphate acyltransferase-1 or -4 inhibited insulin sig-
naling and increased the cellular content of both PA and DAG.
Insulin signaling impairment caused by overexpression of phos-
pholipase D1/D2 or diacylglycerol kinase- was always accompa-
nied by disassociation of mTOR/rictor and reduction of mTORC2
kinase activity. However, although the protein ratio of membrane
to cytosolic PKC increased, PKC activity itself was unaltered.
These data suggest that PA, but not DAG, is associated with
impaired insulin action in mouse hepatocytes.
The accumulation of triacylglycerol in non-adipose tissues is
highly associated with insulin resistance, but the mechanistic
relationship remains unclear. Both diacylglycerol (DAG)2 and
phosphatidic acid (PA) have been implicated as modulators of
insulin signaling that contribute to insulin resistance, but con-
troversy exists as to their sources, their specific roles, and their
mechanism(s) of action (1). PA and DAG are produced via the
pathway of de novo glycerolipid biosynthesis, and PA can also
be produced by phospholipase D (PLD)-mediated phospholipid
hydrolysis and by phosphorylation of DAG by DAG kinase
(DGK). The latter enzyme simultaneously diminishes the DAG
substrate. DAG is believed to cause insulin resistance when it
activates conventional and novel PKC isoforms that inhibit
insulin signaling by serine phosphorylation of insulin receptor
substrate (IRS), thereby decreasing insulin-stimulated tyrosine
phosphorylation (2– 4).
The link between elevated DAG and hepatic insulin resis-
tance is strong (2, 5, 6), but exceptions remain in which hepatic
insulin resistance is unaffected despite elevated DAG content
(7–9) or in which insulin resistance occurs without an increase
in DAG (10). These discrepancies could result from sequestra-
tion in lipid droplets in which the DAG may be unable to acti-
vate PKC because it is poorly accessible (11).
We have reported that PA derived from overexpressing glyc-
erol-3-phosphate acyltransferase (GPAT) or acylglycerol-3-
phosphate acyltransferase (AGPAT) disrupts the association of
mTOR and rictor and inhibits insulin signaling to Akt, thereby
contributing to hepatic insulin resistance (12, 13). In contrast,
PLD-mediated hydrolysis of phosphatidylcholine produces PA
that is said to activate mTORC1 signaling and inhibit insulin
signaling by enhancing IRS1 phosphorylation at serine sites (14,
15). PLD-derived PA also enhances the association of mTOR
and rictor in kidney and breast cancer cells (16). In addition to
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synthesis by PLD, PA can also be generated by phosphorylation
of DAG by one of ten DGK isoforms (17). DGK alters the cel-
lular content of DAG and PA simultaneously and in opposite
directions (18). Although one study showed an association
between DGK inhibition and insulin resistance in skeletal
muscle, the study examined changes in DAG, but not PA (19).
Thus, it is not known whether a DGK-mediated increase in PA
content leads to impaired insulin signaling.
We asked whether one or both of the lipid intermediates, PA
and DAG, is involved in regulating hepatic insulin sensitivity
and whether lipid intermediates that originate from different
enzymatic sources exert different effects. When we overex-
pressed DGK and isoforms of PLD and GPAT in mouse pri-
mary hepatocytes, our results showed that regardless of its
source, elevated PA, particularly PA that contained 16:0 fatty
acid species, was associated with impaired insulin action.
EXPERIMENTAL PROCEDURES
Antibodies and Other Reagents—Primary antibodies were from
Cell Signaling Technology unless otherwise noted. Secondary
antibodies and SuperSignal West Pico chemiluminescent sub-
strate were from Thermo Scientific. Anti-PKC, PKC, PKC, and
DGK antibodies and protein A/G-Sepharose were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-IRS1, anti-Flag M2,
and anti--tubulin antibodies, bovine serum albumin (fatty acid
free), insulin (human recombinant), sodium-D-lactate, phorbol
12-myristate 12-acetate (PMA), Avertin (2-2-2-tribromoethanol),
phosphatase inhibitor cocktails 1 and 2, Percoll, ATP, and CHAPS
were from Sigma. Anti-PLD2 antibody was made as described
(20). Type I collagenase was from Worthington Biochemical Cor-
poration. Protease inhibitor tablets were from Roche. Inactive
Akt1 was from SignalChem (Richmond, Canada). Cell culture
media and reagents were from Invitrogen.
Mouse Liver Perfusion, Hepatocyte Isolation, and Culture—
Hepatocytes were isolated from perfused livers from 8–15-week-
old C57/B6J mice (12) and cultured overnight in William’s
medium E supplemented with 10% FBS, 1% penicillin/strepto-
mycin, and 4 mM glutamine. Hepatocytes were infected with
adenovirus or lentivirus constructs of the different enzymes in
FBS-free William’s medium E supplemented with 1% penicil-
lin/streptomycin and 4 mM glutamine for 24 h, followed by
treatments for specific experiments.
cDNACloning,AdenovirusProduction,andHepatocyteInfection—
The construction, generation, and purification of recombinant
Gpat1-FLAG adenovirus and Ad-enhanced green fluorescent
protein (EGFP) were described previously (21). Gpat3 cDNA
was cloned from an adipocyte cDNA library, and a Flag tag
(Clontech) was added at the carboxyl terminus. Gpat4 cDNA
was cloned as described (22). EGFP, Gpat1-Flag, Gpat3-Flag,
and Gpat4-Flag constructs were subcloned into adenoviral vec-
tors using the AdEasy adenoviral vector system (Stratagene).
EGFP, Gpat1, Gpat3, and Gpat4 adenoviruses were packaged
and titered by the UNC Gene Therapy Core Facility.
Adenoviral constructs of PLD1, PLD2, and the catalytically
inactive mutants of PLD1 and PLD2 were produced as described
(23). MOIs of 10–20 were used for mouse hepatocyte adenoviral
infection, based on pilot experiments to obtain high efficiency of
infection without toxic effects on the cells.
cDNA Cloning, Lentiviral Packaging, and Hepatocyte Infection—
Lentiviral constructs for GFP and mouse DGK were generous
gifts from Dr. Daniel M. Raben (Johns Hopkins University, Bal-
timore, MD). The constructs were transfected into HEK293T
cells together with lentiviral packaging plasmids pCMV delta-
R8.2 and PCMV-VSV-G (Addgene, Cambridge, MA). The
crude lentiviruses (1–2  108 transduction unit/ml) pro-
duced in DMEM containing 4.5 g/liter glucose, 30% FBS, 0.1%
penicillin/streptomycin, and 4 mM glutamine were concen-
trated by 2 h ultracentrifugation at 25,000  g at 4 °C. The
lentivirus pellet was reconstituted in phosphate-buffered saline
to obtain concentrated lentivirus with a titer of 1–2  1010
TU/ml. MOIs of 1 were used for mouse hepatocyte lentiviral
infection, based on pilot experiments to obtain high efficiency
of infection without toxic effects on the cells.
Lipid Extraction and PA and DAG Assays—The total cell lipid
was extracted (24), and PA and DAG were analyzed by LC/MS on
a Shimadzu Prominence ultra fast liquid chromatography system
with a C8 column and detected with an applied Biosystems 4000Q
Trap triple quadripole LC/MS/MS system equipped with an elec-
trospray ionization system as described (12, 25). The amount of
each glycerolipid species in the biological samples was calculated
from the peak areas obtained using the software that controls the
LC/MS system (Analyst 1.5; Applied Biosystems). Raw peak areas
were corrected for recovery and sample loading and then trans-
formed into amounts of analyte using standard curves made with
commercially obtained glycerolipids. To correct for recovery, 0.1
nmol of 17:0 lysophosphatidic acid was added as an internal stand-
ard and normalized to the protein concentrations of the cellular
lysates.
GPAT Activity—Mouse hepatocytes were homogenized in
buffer (10 mM Tris-HCL, pH 7.4, 250 mM sucrose, 1 mM DTT,
1.0 mM EDTA). Total membrane fractions were isolated by cen-
trifuging at 100,000  g for 1 h. Protein concentrations were
determined by the bicinchoninic acid method using bovine
serum albumin as the standard. GPAT specific activity was
assayed for 10 min at 25 °C with 800 M [3H]glycerol-3-phos-
phate and 100 M palmitoyl-CoA. The reaction was initiated by
adding 10 –30 g of total membrane protein to the assay mix-
ture after incubating the membrane protein on ice for 15 min in
the presence or absence of 1 mM NEM, which inhibits GPAT2,
GPAT3, and GPAT4 (26). Microsomal activity (primarily
GPAT3 and GPAT4) (22) was calculated as the activity inacti-
vated by NEM.
PLD Activity—PLD activity was measured as previously described
with [3H]phosphatidylbutanol produced in [3H]palmitate-labeled
hepatocytes through PLD-catalyzed transphosphatidylation
(27). Briefly, 24 h after adenoviral infections, hepatocytes were
labeled for 24 h with [3H]palmitate in the absence of serum. The
labeling medium was then replaced with fresh medium con-
taining 0.3% 1-butanol with or without 100 nM PMA, and 30
min later total cellular lipids were extracted and separated on
Whatman LK5D silica gel thin layer chromatography plates
(with an authentic phosphatidylbutanol positive control) (27,
28) in a developing solvent system of ethyl acetate: 2,2,4-trim-
ethylpentane:acetic acid:water (110:50:20:100, v/v/v/v). The
plate was dried and exposed to iodine. The iodine-stained phos-
phatidylbutanol spot was marked and scraped, as was the
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remainder of the lane. Relative PLD activity was expressed as
the ratio of the scintillation counts in the phosphatidylbutanol
spot to those of the entire lane (27).
DGK Activity—Hepatocytes were lysed on ice with a cold
lysis buffer (40 mM Hepes, pH 7.5, 120 mM NaCl, 1 mM EDTA,
10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF,
0.5 mM Na3VO4, EDTA-free protease inhibitors, 1% phospha-
tase inhibitor mixtures 2 and 3, 0.3% CHAPS). Cell lysates were
centrifuged at 13,000  g for 10 min, and supernatants were
transferred to new tubes. DGK reactions (29, 30) were started
by adding 10 l of the cell lysates (10 –30 g of protein) to 90 l
of a reaction mixture that contained 8 mol% DAG, 16 mol%
phosphatidylserine, 55 mM octylglucoside mixed micelles, 100
M diethylenetriamine pentaacetic acid, 50 mM imidazole HCl,
50 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM DTT, and 1 mM
(2 Ci) [-32P]ATP). The reaction was terminated by adding 1
ml of 1% perchloric acid and 1 ml of chloroform. After vortex-
ing and washing twice with 2 ml of 1% perchloric acid, an ali-
quot of the lower phase (organic) was removed for scintillation
counting.
PKC Activity—Hepatocytes were washed with cold buffer I (20
mM Tris-HCl, pH 7.5, 2.0 mM EDTA, 0.5 mM EGTA, 1 mM phen-
ylmethylsulfonyl fluoride, 1 mM dithiothreitol, and 0.33 M sucrose),
scraped from the dish, centrifuged, and resuspended in cold buffer
I containing 25 g/ml leupeptin and 0.1 mg/ml aprotinin. The cells
were homogenized with 20 up and down strokes at 4 °C in
a motorized Teflon-glass homogenizer. The soluble fraction, ob-
tained after centrifuging at 100,000  g for 60 min, was defined as
the cytosolic extract. The pellets were washed with cold buffer I,
resuspended in cold buffer II (buffer I without sucrose) containing
1% Triton X-100, and homogenized with 10 up and down strokes
at 4 °C. This fraction was defined as the membrane fraction. PKC
activity was assayed with a protein kinase C assay system (Pro-
mega) according to the manufacturer’s instructions. PKC activity
was measured as the calcium-, phosphatidylserine-, and DAG-
stimulated transfer of 32P from [-32P]ATP to the substrate pep-
tide (AAKIQAS*FRGHMARKK; the asterisk indicates that the
preceding serine is the site that is phosphorylated by PKC) and
expressed as pmol [32P]/min/mg protein.
Immunoprecipitation and Kinase Activity Assay—Immuno-
precipitation of rictor and the mTORC2 kinase assay were per-
formed as described (31). Western blots were probed with
phosphor-Akt (Ser-473) to assess mTORC2 activity.
Western Blot Analysis—Hepatocytes were harvested in lysis
buffer (20 mM Tris-HCl, pH 7.5, 0.1 mM Na3VO4, 25 mM NaF, 25
mM glycerophosphate, 2 mM EGTA, 1 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, and 0.3% Triton X-100). The
lysates were mixed 1:1 with 2 Laemmli sample buffer and boiled
before loading onto SDS-PAGE. Western blotting was carried out
according to procedures recommended by suppliers of the anti-
bodies. Horseradish peroxidase-conjugated secondary antibodies
were detected with SuperSignal West Pico chemiluminescent sub-
strate and exposure to x-ray film. The film was converted to digital
images by an Epson scanner (Perfection 2400), and the images
were cropped using Photoshop CS2.
Statistical Analysis—The values are expressed as means 
S.E. Comparisons were determined using Student’s t test (EGFP
or GFP set as control). The data represent at least three inde-
pendent experiments, each performed in triplicate. p  0.05
was considered significant.
RESULTS
Overexpressed PLD1 or PLD2 Impaired Insulin Signaling to
Akt in Mouse Hepatocytes—The PLD-mediated hydrolysis of
phosphatidylcholine to produce PA has taken center stage
in mTOR signaling (32, 33). PA derived via PLD stimulates
mTORC1/S6K1 signaling and increases the phosphorylation of
IRS-1 on serines 307, 632, and 636/639, residues that inhibit
insulin signaling to Akt (34, 35). In contrast to the inhibition
of insulin signaling by mTORC1, insulin signaling is enhanced
by mTORC2, which phosphorylates and activates Akt at serine
473 (31). Because the PA derived via PLD in human kidney and
mammary carcinoma cells stabilizes both mTORC1 and
mTORC2 complexes (16), PA could produce paradoxical out-
comes of both enhanced and inhibited insulin signaling.
To investigate the role of PLD in hepatic insulin signaling, we
overexpressed PLD1 and PLD2 in primary mouse hepatocytes.
Although the antibody for PLD1 also recognizes PLD2, overex-
pression was confirmed by Western blotting (Fig. 1A) by 2-fold
(PLD1) and 25-fold (PLD2) increases in basal activity relative to
EGFP; and by 10-fold (PLD1) and 32-fold (PLD2) increases in
PMA-stimulated PLD activity, respectively (Fig. 1B). Overex-
pressing catalytically inactive PLD1 and PLD2 constructs did
not increase PLD activity (Fig. 1B). Overexpressing PLD1 and
PLD2 in mouse hepatocytes completely blocked insulin signal-
ing, as represented by absent insulin-stimulated Akt phosphor-
ylation at serine 473 and threonine 308. Specificity for these
results was confirmed by the absence of inhibition when the
inactive mutants of PLD1 and PLD2 were used (Fig. 1C). Thus,
PLD-derived signals disrupted insulin signaling in hepatocytes.
Overexpression of PLD1, PLD2, or the inactive PLD constructs
did not alter basal or insulin-stimulated phosphorylation of
IRS1 (Ser-612), consistent with an effect that occurred down-
stream of the insulin receptor (Fig. 1, D and E).
Overexpressing PLD1 and PLD2 Increased the Cellular Con-
tent of Total PA and di16:0 PA, but Did Not Change Total DAG
or di16:0 DAG Content—Our previous study showed that over-
expression of GPAT1 in primary mouse hepatocytes dimin-
ished insulin signaling, blocked phosphorylation of Akt at the
mTORC2 site serine 473, and markedly increased PA species,
particularly di16:0 PA. Furthermore, of several molecular spe-
cies of PA and LPA tested, only diC16:0 PA disrupted the asso-
ciation of mTOR and rictor (12). To determine which lipids
produced by PLD1 and PLD2 were associated with disrupted
insulin signaling in mouse hepatocytes, we examined the cellu-
lar content of PA and DAG species. Compared with cells ex-
pressing EGFP, overexpressed PLD1 increased total PA, 16:0-
containing PA, and the remaining PA species 7.9-, 10-, and
5.8-fold, respectively, and increased di16:0 PA 4.4-fold (Fig. 2, A
and B, and Table 1). Overexpressed PLD2 increased total PA,
16:0-containing PA, and the remaining PA species 1.7-, 1.9-, and
1.5-fold, respectively, and increased di16:0 PA 3.2-fold (Fig. 2, A
and B, and Table 1). Overexpressed PLD1 or PLD2 did not alter the
total DAG content or the content of any DAG species (Fig. 2, C and
D, and Table 2). These results indicate that PA, but not DAG, was
associated with impaired insulin signaling. The eight PA species
PA Correlates with Hepatic Insulin Resistance
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identified were increased 2.6–13-fold by PLD1 overexpression;
however, PLD2 overexpression increased di16:0 PA to the greatest
extent (3.2-fold) (Fig. 2, A and B, and Table 1). Because the block in
Akt phosphorylation was similar with overexpression of either
PLD1 or PLD2 (Fig. 1C), these results suggest that di16:0 PA is
most strongly associated with impaired insulin signaling.
Overexpressed DGK Impaired Insulin Signaling to Akt—
Because PLD overexpression resulted in impaired insulin
signaling, we asked whether PA produced by DGK-mediated
phosphorylation of DAG would similarly inhibit insulin signal-
ing. The DGK reaction is of particular interest because it recip-
rocally modulates the relative concentrations of DAG and PA,
two lipids involved in signal transduction. Although DGK is
expressed in liver (36, 37), little is known about its physiological
function related to insulin signaling. Overexpression of the
DGK protein was confirmed by Western blotting (Fig. 3A) and
by a 4-fold increase in DGK activity (Fig. 3B). Overexpressed
DGK almost completely blocked insulin signaling, as shown by
the absence of insulin-stimulated Akt phosphorylation at serine
473 and threonine 308 (Fig. 3C). Overexpressing DGK did not
alter the phosphorylation of IRS1 (Ser-612) (Fig. 3, D and E), sug-
gesting that the lipid signal derived from DGK had disrupted the
insulin signaling pathway downstream of IR/IRS1.
Overexpressing DGK Increased the Cellular Content of Total
PA and di16:0 PA, and Decreased Total DAG and di16:0
DAG—To learn which lipid signals produced by DGK were
associated with impaired hepatic insulin signaling, we overex-
pressed DGK in mouse hepatocytes and examined the cellular
content of PA and DAG. Compared with the GFP control, over-
expressing DGK increased total PA, 16:0-containing PA spe-
cies, and the remaining PA species by 2.3-fold and increased
di16:0 PA 9.4-fold (Fig. 4, A and B, and Table 1). Overexpressing
DGK decreased total DAG, 16:0-containing DAG, and other
FIGURE 1. Overexpressing PLD1 and PLD2 impaired insulin signaling to Akt. Mouse primary hepatocytes were infected for 24 h with EGFP, Flag-GPAT1,
PLD1, inactive PLD1 mutant (PLD1-m), PLD2, or inactive PLD2 mutant (PLD2-m) adenoviruses. Cells were lysed and subjected to Western blotting with
appropriate antibodies (A), scraped from the dish, centrifuged to obtain total particulate preparations and assayed for PLD activity (B), or treated with or
without insulin (100 nM) for 10 min, followed by cell lysate preparation for Western blotting (C and D). A, C, and D show representative Western blots from three
independent experiments; B shows results from three independent experiments, each done in triplicate. E shows the quantitative analysis of data from D. * and
#, p  0.05 compared with EGFP basal and PMA-stimulated, respectively.
FIGURE 2. Overexpressing PLD1 and PLD2 increased the cellular content
of total PA and di16:0 PA but did not change total or di16:0 DAG. Lipids
were extracted from mouse primary hepatocytes overexpressing EGFP, PLD1,
or PLD2. A, content of total PA, 16:0-containing PA, and other PA. B, content of
di16:0 PA. C, content of total DAG, 16:0-containing DAG, and other DAG. D,
content of di16:0 DAG. *, p  0.05 compared with EGFP. The data are from
three independent experiments, each done in triplicate.
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DAG species by 71, 91, and 27%, respectively, and decreased
di16:0 DAG by 95% (Fig. 4, C and D, and Table 2). These results
show a strong association between diminished insulin signaling
FIGURE 3. Overexpressing DGK impaired insulin signaling to Akt in
mouse hepatocytes. Mouse primary hepatocytes were infected for 24 h with
GFP or DGK lentiviruses. Cells were lysed and subjected to Western blotting
with appropriate antibodies (A), lysed and assayed for DGK activity (B), or
treated with or without insulin (100 nM) for 10 min, followed by cell lysate
preparation for Western blotting (C and D). A, C, and D show representative
Western blots from three independent experiments; B shows results from
three independent experiments, each done in triplicate. E shows the quanti-
tative analysis of data from D. *, p  0.05 compared with GFP.
FIGURE 4. Overexpressing DGK increased the cellular content of total PA
and di16:0 PA and decreased total DAG and di16:0 DAG. Lipids were
extracted from mouse primary hepatocytes overexpressing GFP or DGK, and
lipid content was assayed. A, content of total PA, 16:0-containing PA, and
other PA. B, content of di16:0 PA. C, content of total DAG, 16:0-containing
DAG, and other DAG. D, content of di16:0 DAG. The data are from three inde-
pendent experiments, each done in triplicate. *, p  0.05 compared with GFP.
TABLE 1
Content of PA species in mouse primary hepatocytes overexpressing EGFP, GPAT3, GPAT4, PLD1, PLD2, GFP, or DGK
Mouse primary hepatocytes were infected for 24 h with 1) EGFP, Flag-GPAT3, or Flag-GPAT4 adenoviruses, or with 2) EGFP, HA-PLD1, or HA-PLD2 adenoviruses, or with
3) GFP or DGK lentiviruses. Lipids were extracted and PA content was analyzed as described under “Experimental Procedures.” Comparisons were determined using
Student’s t test.
PA
species EGFP1 GPAT31 GPAT41 EGFP2 PLD12 PLD22 GFP3 DGK3
pmol/mg
protein









16:0–16:0 0.56  0.26 1.0  0.49 3.17  1.58a 0.73  0.29 3.21  0.76a 2.32  0.41a 0.9  0.33 8.45  2.15a
16:0–18:0 0.77  0.33 2.42  0.23a 2.86  1.12a 0.54  0.21 2.54  0.83a 0.8  0.23 1.15  0.41 2.49  0.33a
16:0–18:1 11.62  2.25 12.62  3.46 37.9  12.16a 14.06  7.81 170.9  56.8a 30.06  10.2a 15.31  6.1 22.7  4.06
16:0–18:2 7.67  1.83 8.35  3.25 30.17  9.55a 5.91  1.05 34.12  10.4a 8.23  1.67 7.22  0.47 22.18  5.16a
18:0–18:1 4.39  0.95 12.34  2.96a 19.94  9.82a 4.12  0.89 10.86  1.51a 2.69  0.45 5.79  0.98 7.17  0.86
18:0–18:2 1.86  0.33 3.81  0.44a 4.56  1.38a 1.94  0.64 25.43  6.1a 4.75  1.37a 1.53  0.18 0.24  0.11
18:1–18:1 13.3  3.68 57.02  6.91a 68.96  16.9a 13.27  0.88 72.7  9.25a 21.62  4.4a 12.08  3.71 36.82  1.54a
18:1–18:2 1.2  0.26 4.23  0.48a 8.13  2.42a 1.59  0.68 11.53  1.98a 2.52  0.3 1.35  0.23 3.53  0.76a
Total 41.37  8.99 101.8  16.38a 175.69  53.8a 42.16  10.5 331.3  78.3a 72.99  18a 45.33  5.99 103.58  6.29a
a p  0.05 compared to EGFP, EGFP, or GFP as grouped by superscripts 1, 2, or 3. Data are from three independent experiments, each done in triplicate.
TABLE 2
Content of DAG species in mouse primary hepatocytes overexpressing EGFP, GPAT3, GPAT4, PLD1, PLD2, GFP, or DGK
Mouse primary hepatocytes were infected for 24 h with 1) EGFP, Flag-GPAT3, or Flag-GPAT4 adenoviruses, or with 2) EGFP, HA-PLD1, or HA-PLD2 adenoviruses, or with
3) GFP or DGK lentiviruses. Lipids were extracted and DAG content was analyzed as described under “Experimental Procedures.” Comparisons were determined using
Student’s t test.
DAG

















16:0–16:0 7.44  1.69 7.21  0.72 10.81  1.83a 7.62  1.29 7.35  1.75 8.07  1.01 10.0  0.93 0.46  0.08a
16:0–18:0
16:0–18:1 12.37  2.42 16.14  2.21a 46.13  10.3a 14.19  5.04 15.88  5.36 16.39  4.07 12.2  0.45 1.23  0.2a
16:0–18:2 3.25  0.72 3.09  0.49 7.58  1.44a 3.29  0.46 2.76  0.32 3.15  0.15 4.43  0.58 0.81  0.09a
18:0–18:1
18:0–18:2
18:1–18:1 12.81  2.3 16.62  1.85a 15.24  6.24 10.47  0.92 11.55  0.4 10.73  1.09 8.52  0.69 6.9  1.02a
18:1–18:2 2.21  0.54 2.0  0.35 2.23  0.86 2.44  0.41 2.8  0.63 2.83  0.59 3.3  0.72 1.7  0.54a
18:2–18:2 1.56  0.3 1.41  0.24 1.19  0.49a 1.37  0.16 1.58  0.24 1.64  0.15
Total 39.64  7.84 46.47  5.15 83.18  19.4a 39.38  6.65 41.92  8.29 42.81  6.95 38.45  2.93 11.1  1.18a
a p  0.05 compared to EGFP, EGFP, or GFP as grouped by superscripts 1, 2, or 3. Data are from three independent experiments, each done in triplicate.
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and the hepatocyte content of PA, especially di16:0 PA, but not
with DAG content or species.
Overexpressing Gpat1 or Gpat4, but Not Gpat3, Impaired
Insulin Signaling to Akt—In addition to PLD and DGK, increas-
ing flux through the glycerolipid biosynthetic pathway can
increase cellular PA content. Overexpressing GPAT1 in rat
liver increases hepatic triacylglycerol content and induces
hepatic insulin resistance (36), and overexpressing GPAT1 in
cultured mouse hepatocytes diminishes insulin-mediated sup-
pression of glucose production by disrupting the association
between mTOR and rictor (12). Of the four GPAT isoforms
found in mammals, GPAT1 and GPAT2 are located on the
outer membrane of mitochondria, and GPAT3 and GPAT4
reside on the endoplasmic reticulum (26) and on lipid droplets
(37). GPAT1 has a strong substrate preference for 16:0-CoA,
and GPAT4 shows a mild preference for acyl-CoAs that contain
16 and 18 carbons, but GPAT2 and GPAT3 exhibit no acyl-CoA
specificity (22, 38). To investigate the roles of different GPAT
isoforms in regulating insulin sensitivity, we overexpressed
GPAT1, GPAT3, and GPAT4 in mouse primary hepatocytes by
infecting the cells with adenovirus-GPAT isoforms that each
contained a carboxyl-terminal Flag tag. Overexpression was
confirmed by Western blotting (Fig. 5A) and by 5-fold
(GPAT1), 4-fold (GPAT3), and 5.5-fold (GPAT4) increases in
total GPAT activity (Fig. 5B), consistent with our previous stud-
ies (13). Overexpressing either GPAT3 or GPAT4 increased
NEM-sensitive GPAT activity, whereas overexpressing GPAT1
increased NEM-resistant GPAT activity (Fig. 5B), consistent
with the fact that GPAT1 is NEM-resistant and GPAT3 and
GPAT4 are NEM-sensitive (26). Overexpressing GPAT1 or
GPAT4 completely blocked insulin signaling to Akt as shown
by absent Akt phosphorylation at serine 473 and threonine 308,
the sites that are essential for full Akt activation. In contrast,
overexpressing GPAT3 did not result in diminished Akt phos-
phorylation (Fig. 5C). These results replicate our previous
report (13) and suggest (a) that signals from the GPAT-initiated
pathway of lipid synthesis impair insulin signaling and (b) that
the location of the GPAT isoform does not determine its effect
on insulin sensitivity.
Overexpressing GPAT4, but Not GPAT3, Increased the Cellu-
lar Content of Total PA and DAG, and di16:0 PA, but Not di16:0
DAG—In mouse hepatocytes that overexpressed GPAT1, inhi-
bition of insulin signaling correlates with increases in the cellu-
lar content of both DAG and PA, particularly 16:0-containing
PA and di16:0 PA (12). To learn whether this correlation exists
for other GPAT isoforms, we examined the cellular content of
PA and DAG in mouse hepatocytes that overexpressed GPAT3
or GPAT4. GPAT4 overexpression increased the content of
total PA 4-fold, and di16:0-PA species 3.6-fold, and non-16:
0-PA species 4.9-fold (Fig. 6A and Table 1), consistent with
a previous study (13). In contrast, GPAT3 overexpression
increased the content of total PA 2.5-fold, but this increase
was in non-16:0-PA species (Fig. 6, A and B, and Table 1).
GPAT4 overexpression also increased the total DAG content
and the content of DAG species containing 16:0, but GPAT3
overexpression did not alter the content of DAG (Fig. 6, C and
D, and Table 2). Thus, the cellular content of both PA and DAG,
especially the di16:0 PA and DAG species, correlated with
diminished insulin signaling.
Overexpression of PLD1 or 2 or DGK Diminished the mTOR-
Rictor Association and Inhibited mTORC2 Activity—To test the
mechanism by which overexpressing PLD1/2 and DGK
blocked insulin signaling, we immunoprecipitated rictor and
assayed mTORC2 kinase using inactive Akt as the substrate.
The expression of all three enzymes, PLD1, PLD2 and DGK,
disrupted the mTOR-rictor association (Fig. 7, A and B) and
inhibited mTORC2 activity (Fig. 7, A and C), indicating that
similar to the overexpression of GPAT1 or GPAT4 in mouse
FIGURE 5. Overexpressed GPAT1 and GPAT4 in mouse hepatocytes, but
not GPAT3, impaired insulin signaling to Akt. Mouse primary hepatocytes
were infected for 24 h with EGFP, Flag-GPAT1, Flag-GPAT3, or Flag-GPAT4
adenoviruses. Cells were lysed and subjected to Western blotting with anti-
Flag antibodies (A); scraped from the dish, centrifuged to obtain total partic-
ulate preparations, and assayed for total and NEM-resistant (NEM-R) GPAT
activity (B); or treated with or without insulin (100 nM) for 10 min, followed by
cell lysate preparation for Western blotting (C). A and C show representative
Western blots from three independent experiments; B shows data from three
independent experiments, each done in triplicate. * and #, p  0.05 compared
with EGFP total and NEM-resistant GPAT activity, respectively.
FIGURE 6. Overexpressing GPAT4, but not GPAT3, increased the cellular
content of total PA, DAG, and di16:0 PA. Lipids were extracted from mouse
primary hepatocytes overexpressing EGFP, Flag-GPAT3, or Flag-GPAT4, and
lipid content was assayed. A, content of total PA, 16:0-containing PA, and
other PA. B, content of di16:0 PA. C, content of total DAG, 16:0-containing
DAG, and other DAG. D, content of di16:0 DAG. The data are from three inde-
pendent experiments, each done in triplicate. *, p  0.05 compared with
EGFP.
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hepatocytes (12, 13), the overexpression of PLD1, PLD2, or
DGK blocked insulin signaling by disrupting the mTOR-rictor
association and inhibiting mTORC2 activity.
Overexpression of GPAT1 and GPAT4 Increased the Protein
Ratio of Membrane to Cytosolic PKC but Did Not Alter PKC
Activity—DAG is believed to inhibit insulin signaling in liver by
recruiting and activating PKC at the membrane (5). However,
as with a previous report that focused on GPAT1 (12), express-
ing the GPAT4 isoform was not helpful in distinguishing
between the roles of PA and DAG as regulators of insulin sig-
naling. Therefore, to determine whether the increased DAG
content present in GPAT4 overexpressing cells had interfered
with insulin signaling, we asked whether the location and activ-
ity of PKC had changed. The locations of PKC and PKC did
not change, but as previously reported for overexpression of
GPAT1 in rat liver (36), overexpressing either GPAT1 or
GPAT4 increased the ratio of membrane to cytosolic PKC
protein (Fig. 8A), a ratio that is often accepted as a proxy for
PKC activation. However, similar to a previous report (39), this
change resulted from a reduction in the cytosolic content of
PKC, although the membrane PKC content did not change
(Fig. 8B). More importantly, PKC activity itself did not increase,
in contrast to the 2.5-fold increase in activity produced by the
PMA control (Fig. 8C). The decrease in cytosolic DAG may
have resulted from sequestration of DAG in lipid droplets
where it would not be accessible to membrane-associated PKC
(11). These data suggest that when GPAT is overexpressed in
cultured mouse hepatocytes to induce increased glycerolipid
synthesis, PA molecules that contain 16:0 acyl groups are the
lipid intermediates most likely to inhibit the insulin signaling
pathway.
DISCUSSION
In the current study, we manipulated the cellular content of
PA and DAG by overexpressing key enzymes that catalyze the
production of these two lipid intermediates and demonstrated
that the cellular content of PA, but not DAG, correlates closely
with the inhibition of insulin signaling in mouse hepatocytes.
Lipin, which synthesizes DAG from PA, was not included in
this study because we previously reported that overexpressing
Lipin2 does not inhibit insulin signaling in mouse hepatocytes;
the overexpression of Lipin2 results in only a 1.24-fold increase
in total PA with no change in di16:0 PA or total DAG (12).
PLD-derived PA appears to promote mTOR-raptor assem-
bly, thereby activating mTORC1, which inhibits insulin signal-
ing by enhancing IRS1 phosphorylation at serine sites (14, 16).
We have reported that GPAT1-derived PA disrupts the assem-
bly of mTOR and rictor, thereby diminishing phosphorylation
of phospho-Akt (Ser-473) and inhibiting insulin signaling (12).
Others, however, have shown that PLD-derived PA promotes
the assembly of both mTOR-raptor and mTOR-rictor (16, 33).
How can chemically identical molecules have opposite func-
tions? It was proposed that because different PA-producing
enzymes are located on or within specific subcellular organ-
elles, the PA molecules produced by these enzymes might func-
tion differently because of their cellular compartmentalization
(1, 26, 41). PA derived from GPAT (via AGPAT) is produced at
the outer mitochondrial membrane, at the lipid droplet, or at
the ER surface (26, 42, 43); the PA produced by PLD1 is present
in the Golgi and the nucleus (44); and DGK produces PA at the
plasma membrane, ER, and nucleus (45). However, because our
previous and current data show that each of three different
catalytic pathways, GPAT/AGPAT, PLD, and DGK, provides
PA that inhibits insulin signaling to Akt, the ability of PA to
disrupt insulin signaling suggests that the effect of the PA may
be unrelated to its source. Instead, the ability of PA to stabilize
or disrupt mTORC may depend on the length and saturation of
its fatty acid chains (1, 41). Our work has shown that overex-
pressing any of five enzymes in mouse hepatocytes, GPAT4,
PLD1, PLD2, DGK, or GPAT1, impaired insulin signaling
(Figs. 1, 3, and 5) and significantly increased the content of PA,
particularly di16:0 PA (Figs. 2, 4, and 6 and Table 1). Although
the hepatic PA content produced by GPAT3 was similar to that
produced by DGK, it did not inhibit Akt phosphorylation, sup-
porting the idea that the individual PA species are more critical
than the amount of PA. This result is consistent with our pre-
vious report that of 10 lysoPA, DAG, and PA species tested,
only di16:0 PA interfered with mTORC2 assembly (13).
Although many studies have concluded that DAG-mediated
activation of PKC inhibits insulin signaling (2), divergent work
has been reported. In both animal and human studies, elevated
DAG content caused by lipid infusion or overload does not lead
to suppressed insulin action or to insulin resistance, and insulin
resistance is not always accompanied by increases in DAG con-
tent (1, 7–9). The current study provides data from cultured
primary mouse hepatocytes showing that insulin resistance
does not always correlate with DAG content and that the ratio
of membrane to cytosolic PKC protein is not invariably a proxy
for PKC activation.
Of the nine PKC isoforms, PKC has been most widely
reported as activated by DAG in liver to suppress insulin action
(5). However, the different DAG species vary in their ability to
activate PKC (41). Activation of PKC requires stereospecific
FIGURE 7. Overexpressing PLD1, PLD2, or DGK diminished mTOR-rictor
association and inhibited mTORC2 activity. Mouse primary hepatocytes
overexpressing EGFP, PLD1, PLD2, or DGK were lysed and immunoprecipi-
tated (IP) and then assayed for mTORC2 kinase activity followed by Western
blotting. A, Western blots representative of three independent experiments.
B and C, quantitative analysis of data from A. *, p  0.05 compared with EGFP.
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1,2-sn-diacylglycerols (46). The 1,2-sn-di18:1 DAG and 1,2-sn-
di20:4 DAG show the strongest stimulatory effect on PKC
activity, and sn-1–18:0 –2-18:1 DAG, sn-1–18:0 –2-18:2 DAG,
and sn-1,2-di18:2 DAG are also effective (47). However, most
studies in which an increase in tissue content of DAG has been
reported to activate PKC and cause insulin resistance have not
distinguished among DAG species, making it unclear whether
the activation was caused by an increase in total DAG or by a
particular DAG species. We previously reported that overex-
pressing GPAT1 or AGPAT2 in mouse hepatocytes inhibited
insulin signaling; this inhibition was accompanied by increases
in the cellular content of both PA and DAG, suggesting that
both these lipids might impair insulin signaling (12). When we
identified the lipid species, we determined that overexpressing
GPAT1 or AGPAT2 did not increase the reportedly effective
DAG species, di18:1 DAG and 18:1–18:2 DAG. Our data sug-
gested that although total DAG content increased 1.5–2.2-fold
when GPAT1 or AGPAT2 was overexpressed, DAG might not
have been the major inhibitor of insulin signaling (12). In the
current study, both overexpressed PLD1 and PLD2 impaired
insulin signaling in mouse hepatocytes but did not increase
total DAG content, while only minimally increasing di18:1
DAG and 18:2–18:2 DAG (Figs. 1 and 2 and Table 2). In addi-
tion, overexpressing DGK impaired insulin signaling in mouse
hepatocytes and decreased, rather than increased, total DAG
and di18:1 DAG (Figs. 3 and 4 and Table 2). These results dis-
sociate inhibited insulin signaling from hepatocyte DAG con-
tent. Similarly, although overexpressing GPAT4 in mouse
hepatocytes impaired insulin signaling, PKC was not activated
despite a 2.1-fold increase in total DAG content, perhaps
because the DAG was sequestered in lipid droplets or because
di18:1 DAG content increased only 20% and di18:2 DAG
decreased.
Although some early studies of hepatic insulin resistance
directly measured the activity of PKC, these studies did not
show a correlation between hepatic insulin resistance, PKC
activation, and increased DAG content (48, 49). Except for a
single paper that measured PKC activity (50), the majority of
recent studies of PKC activity and hepatic insulin resistance
measured only the ratio of membrane to cytosolic PKC pro-
tein. The current study shows that the increase in this ratio does
not necessarily represent a change in PKC activity; in the pres-
ent case, the ratio changed because the amount of cytosolic
PKC protein consistently decreased in numerous prepara-
tions. A similar discrepancy in the ratio of membrane to cyto-
solic PKC and  proteins and PKC activity was reported in
mice with deficient hepatic MGAT1 (39). Notably, overex-
pressing any of five enzymes did not change IRS1 phosphory-
lation at serine 612 (Figs. 1, D and E, and 3, D and E), the site that
is specifically phosphorylated by PKC (3), providing additional
evidence that DAG does not mediate the inhibition of insulin
signaling by these enzymes. The most direct evidence for DAG
activation of PKC comes from in vitro studies in which purified
PKC protein was added to a reaction system in which a synthe-
sized peptide substrate was present together with phospholip-
ids, Ca2, and ATP, in the presence or absence of DAG. Results
of in vitro studies showed 2– 6-fold increases in PKC activity
when particular species of DAG were present (40, 47). Because
conventional and novel PKC isoforms are activated by DAG,
many commercial kits for PKC assay include DAG in the acti-
vation or coactivation buffer, which makes it unclear as to
whether changes observed in PKC activity are caused by endog-
enous or exogenous DAG. Acute changes in DAG may not play
the same role in live cells in which PKC might have already
interacted with cellular DAG and might not be further affected
by the DAG provided in commercial kits.
Our study has two potential limitations. Although the enzyme
activities are within normal ranges for mammalian tissues, they do
result from the overexpression of enzymes whose subcellular loca-
tions are not known, so it is possible that PA produced endoge-
nously by each of these pathways would not have the same effect. A
second caveat is that the primary hepatocytes were cultured in
FIGURE 8. Overexpressing GPAT1 or GPAT4 increased the protein ratio of membrane to cytosolic PKC but did not alter PKC activity. Membrane and
cytosolic preparations from mouse primary hepatocytes overexpressing EGFP, Flag-GPAT1, Flag-GPAT3, or Flag-GPAT4 were subjected to Western blotting (A)
and protein quantification (B) or assayed for PKC activity (C). A and B show representative Western blots and protein quantifications from three independent
experiments; C shows data from three independent experiments, each done in triplicate. *, p  0.05 compared with EGFP.
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Williams’s medium E, which provides 5.5 mM glucose as the major
energy source. The glucose may have enhanced ChREBP-con-
trolled de novo lipogenesis, thereby increasing the production of
16:0 fatty acids that were then incorporated into PA via the GPAT
pathway and into phospholipids available for PLD hydrolysis.
Finding a relationship between an increased cellular content
of distinct PA species and impaired insulin signaling provides
a new therapeutic target for treatment of insulin resistance.
However, the mechanism for PA action in regulating insulin
signaling requires further study. Although we have reported
that di16:0 PA disrupts mTOR/rictor assembly in vitro, the
mechanisms that underlie this disruption and the interaction of
di16:0 PA with mTORC2 are not known. Likewise, a full under-
standing of the molecular mechanism of lipid intermediate-
mediated insulin resistance may also require the identification
of particular DAG species that effectively activate PKC.
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